**Core Concept**
Interferon-alpha and interleukin-2 (IL-2) are immunostimulants used in the treatment of various cancers, including malignant melanoma. These agents work by enhancing the body's immune response against cancer cells.

**Why the Correct Answer is Right**
Aldesleukin, also known as recombinant interleukin-2 (rIL-2), is a synthetic form of IL-2 that stimulates the growth and activity of T lymphocytes. This leads to an increased immune response against cancer cells, including those found in malignant melanoma. Aldesleukin has been shown to be effective in treating metastatic melanoma, particularly in patients with a good performance status. The mechanism of action involves the activation of T cells, which then release cytokines that induce an antitumor response.

**Why Each Wrong Option is Incorrect**
**Option A:** Levamisole is an immunomodulator that has been used to stimulate the immune system in patients with cancer, but it is not specifically used for the treatment of malignant melanoma. Levamisole works by increasing the production of antibodies and activating immune cells, but it is not as effective as IL-2 in treating melanoma.
**Option B:** BCG (Bacillus Calmette-Guérin) is a live attenuated vaccine used primarily for the treatment of superficial bladder cancer. While BCG does stimulate an immune response, it is not used for the treatment of malignant melanoma.
**Option D:** Methotrexate is a chemotherapeutic agent used to treat various types of cancer, including leukemia, lymphoma, and breast cancer. However, it is not an immunostimulant and is not used for the treatment of malignant melanoma.

**Clinical Pearl / High-Yield Fact**
Aldesleukin is a high-risk medication that requires careful monitoring due to its potential to cause severe side effects, including hypotension, rash, and respiratory failure. Patients receiving aldesleukin should be closely monitored for signs of immune activation and be prepared for rapid intervention if necessary.

**✓ Correct Answer: C. Aldesleukin**